EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Thomas Huang; Brigitte J. Engelmann; Rachael M. Morgan; Kimberly J. Absher; Jill M. Kolesar; John L. Villano

doi:10.1007/s00280-018-3571-2

EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Thomas Huang, Brigitte J. Engelmann, Rachael M. Morgan, Kimberly J. Absher, Jill M. Kolesar, John L. Villano

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

EML4–ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4–ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4–ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4–ALK genomic testing may be clinically useful in patients with heavy smoking history.

Original language	English
Pages (from-to)	965-968
Number of pages	4
Journal	Cancer Chemotherapy and Pharmacology
Volume	81
Issue number	5
DOIs	https://doi.org/10.1007/s00280-018-3571-2
State	Published - May 1 2018

Bibliographical note

Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords

Alectinib
Anti-ALK inhibitor treatment
Crizotinib
EML4–ALK translocation
Smoking
Squamous cell lung cancer

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-018-3571-2

Cite this

@article{b13eee3be4a34eb982d1401f995eca98,

title = "EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib",

abstract = "EML4–ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4–ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4–ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4–ALK genomic testing may be clinically useful in patients with heavy smoking history.",

keywords = "Alectinib, Anti-ALK inhibitor treatment, Crizotinib, EML4–ALK translocation, Smoking, Squamous cell lung cancer",

author = "Thomas Huang and Engelmann, {Brigitte J.} and Morgan, {Rachael M.} and Absher, {Kimberly J.} and Kolesar, {Jill M.} and Villano, {John L.}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2018",

month = may,

day = "1",

doi = "10.1007/s00280-018-3571-2",

language = "English",

volume = "81",

pages = "965--968",

number = "5",

}

TY - JOUR

T1 - EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

AU - Huang, Thomas

AU - Engelmann, Brigitte J.

AU - Morgan, Rachael M.

AU - Absher, Kimberly J.

AU - Kolesar, Jill M.

AU - Villano, John L.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - EML4–ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4–ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4–ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4–ALK genomic testing may be clinically useful in patients with heavy smoking history.

AB - EML4–ALK alterations are more common in adenocarcinomas and are rarely found in squamous cell histology. In documented cases, the majority of EML4–ALK translocations are identified in squamous cell histology and occur in patients with no or light smoking history. We report an EML4–ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests that EML4–ALK genomic testing may be clinically useful in patients with heavy smoking history.

KW - Alectinib

KW - Anti-ALK inhibitor treatment

KW - Crizotinib

KW - EML4–ALK translocation

KW - Smoking

KW - Squamous cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85044715698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044715698&partnerID=8YFLogxK

U2 - 10.1007/s00280-018-3571-2

DO - 10.1007/s00280-018-3571-2

M3 - Article

C2 - 29610932

AN - SCOPUS:85044715698

SN - 0344-5704

VL - 81

SP - 965

EP - 968

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 5

ER -

EML4–ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this